Genic제닉

Genic's profits surged in 2025 and H1 2026, but its share price has fallen about 27% over the past month.

Genic, a Korean cosmetics maker known for hydrogel mask packs and OEM/ODM supply, reported trailing twelve-month revenue of ₩114.3B and net income of ₩29.6B to H1 2026. The shares closed at ₩17,690 on 2026-10-21, down 14.5% over one year and well below the 52-week high of ₩38,900. The company's own DCF model gives a base value of ₩3,426, a bear value of ₩0 and a bull value of ₩13,870, which the data presents without endorsement.

What stands out

• Revenue grew 56.7% in 2025 to ₩78.2B after falling in 2022 and 2023, and operating margin reached 19.1% in 2025.
• Trailing net income (₩29.6B) is well above operating income (₩19.2B), so non-operating items or one-offs may matter; the data does not explain this.
• Free cash flow was negative at about -₩0.9B on a trailing basis, while borrowings stand at ₩3.0B against cash of ₩3.7B.
• Foreign ownership rose from 1.4% to 7.7% over about 60 days, while institutions and retail were net sellers over the past 20 days.
• Valuation multiples are low (P/E 4.8, P/B 2.5, EV/EBITDA 6.6) and the company pays no dividend; recent filings include a decision to increase short-term borrowings on 2026-07-20.

What to watch

• The Q3 2026 quarterly report and any update on whether profitability holds after 2025's strong year.
• Further filings on short-term borrowings, following the July 2026 decision to increase them.
• Recent news headlines are absent from the data, so the reasons behind the share price fall are not explained here.